Roth Capital analyst Boobalan Pachaiyappan raised the firm’s price target on Entrada Therapeutics (TRDA) to $19 from $13 and keeps a Buy rating on the shares. With the positive opinion from Data Monitoring Committee, DMC, of Cohort 1 safety and PK data, focus now shifts to top-line readout expected in Q2, and assuming acceptable safety characteristics without abnormal renal biomarkers and dystrophin expression improvement, Entrada may revive the dialog with the FDA to kickstart ENTR-601-44 evaluation in U.S. ambulatory DMD44 patients, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
- Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
- Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
- Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
- Entrada Therapeutics initiated with a Buy at Guggenheim